Japan's Mitsubishi Tanabe Plans Scaled Entry Into U.S. Market
This article was originally published in PharmAsia News
Mitsubishi Tanabe Pharma has plans to enter the U.S. pharmaceutical market in two years, beginning with a pair of drugs to treat kidney problems. To market the drugs, Mitsubishi Tanabe also plans to set up a U.S.-based sales unit and hire 100 representatives. The company expects to apply next year for U.S. approval of a hyperphosphatemia drug to treat kidney dysfunction as its first product. A year later, it plans to file for a treatment for chronic kidney failure with the hope of launching both drugs in 2012 or 2013. Longer-range plans call for introducing a diabetes treatment, along with entering into marketing agreements and acquiring U.S. companies. (Click here for more - a subscription may be required
You may also be interested in...
J&J expects its medical device sales to begin growing rapidly by the middle of 2021 as the pandemic subsides.
US FDA drugs center’s ambitious guidance agenda lists 105 new or revised guidances, most of which carried over from the prior year; new to the list are three guidances each on real-world data and individualized antisense oligonucleotide drug products, and a document focused on demonstrating efficacy with a single adequate and well-controlled trial.
The company said data show a lower overall infection rate and no symptomatic infections among participants receiving the drug, compared with placebo.